YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Scientists inside a laboratory] Hinterhaus Productions The Food and Drug Administration and Duke-Margolis Institute for Health Policy will convene a public workshop this month to examine one of the most difficult questions in rare disease…
* Silence Therapeutics (SLN [https://seekingalpha.com/symbol/SLN]) priced an upsized underwritten public offering of 12.96M ADSs at $13.50 each, raising ~$175M in gross proceeds. * The underwriters have a 30-day option to purchase up to an…
(RTTNews) - Silence Therapeutics plc (SLN), a biotechnology company, announced a proposed public offering for $150 million worth of American Depositary Shares (ADSs). Each ADS represents £0.05 in capital of the company in the U.S. Underwri…
(RTTNews) - The following biotech stocks reached a 52-week high on August 10, 2026, driven by key catalysts such as positive quarterly reports or the release of promising results from clinical trials. Silence Therapeutics plc (SLN) Silence…
Investing.com - U.S. stock index futures edged higher on Monday, while Dow futures were little changed, as investors scaled back hopes for a breakthrough in the Middle East and looked ahead to key inflation data due later this week for fre…
Researcher looking through microscope ©Adobe Stock Images Silence Therapeutics (NASDAQ:SLN) shares jumped 16.2% in pre-market trading on Monday as investors positioned ahead of a conference call covering topline results from the Phase 2 SA…
European equities traded in the US as American depositary receipts started the week off lower late M PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
(RTTNews) - The following biotech stocks reached a 52-week high on July 22, 2026, driven by key catalysts including prospective clinical trial results and announced acquisitions. Advanced Biomed Inc. (ADVB) Advanced Biomed is a biotechnolo…
Shares of Silence Therapeutics SLN have surged 107% over the past six months, driven by investor optimism around the company's advancing RNA interference (siRNA) pipeline, upcoming clinical data readouts and the long-term growth potential…
Silence Therapeutics PLC Sponsored ADR (SLN) shares soared 7.2% in the last trading session to close at $10.45. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's…
Silence Therapeutics PLC Sponsored ADR (SLN) shares soared 7.2% in the last trading session to close at $10.45. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's…
[Technology background image, graph, displaying analytical data about stock trading.] Donny DBM William Blair added Oracle (ORCL [https://seekingalpha.com/symbol/ORCL]), American Express (AXP [https://seekingalpha.com/symbol/AXP]), Ecolab…
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Silence Therapeutics plc (NASDAQ:SLN) is one of the most promising stocks on our list. TheFly reported on June 24 that Cantor Fitzgerald…
(RTTNews) - Today's top gainers include Pulsenmore, which has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the United States; IceCure Medical, whose ProSense technology was validated in a…
European equities traded in the US as American depositary receipts were trending higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were trending lower late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
European equities traded in the US as American depositary receipts were tracking lower late Thursday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were lower late Wednesday morning PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were higher late Wednesday mornin PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts began the week little changed lat PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were lower late Thursday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were tracking sharply higher late PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were sliding late Thursday mornin PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
European equities traded in the US as American depositary receipts were tracking higher late Wednesd PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
As February begins, the U.S. stock market is showing strength, with major indexes like the Dow Jones and S&P 500 posting significant gains. In this context of rising indices, investors often look for opportunities that may offer growth pot…
Key Points Lombard Odier Asset Management (USA) Corp sold 3,334,000 shares of Bausch Health Companies; position value declined by approximately $22,564,800 Change represents approximately 1.53% of Lombard Odier Asset Management (USA) Corp'…
The biotech sector has long offered investors high-risk, high-reward stocks. While large players are making headlines, the next wave of breakthroughs may come from companies flying well below Wall Street’s radar. These five under-the-radar…
We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against other takeover rumor stocks hedge funds are buying. Hedge…
Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030. Efficiencies could contribute $1.5 trillion to the…
Wall Street likes to peer into the fog of the future and guess where a stock is headed. While these stock price predictions are based on educated estimates, often based on information and models unavailable to regular investors, they are n…
Biotech stocks can offer some of the most explosive, exciting opportunities on the market. That is, if you find the right one. Viking Therapeutics (NASDAQ:VKTX) is the perfect example. Interest in weight loss medications is skyrocketing ju…
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation. First, the hard data supports bullishness in biotech stocks. According to Grand View Research, the underlying global industry…
Key Insights Significant insider control over Silence Therapeutics implies vested interests in company growth 53% of the business is held by the top 4 shareholders Institutions own 24% of Silence Therapeutics A look at the shareholders of…
Silence Therapeutics PLC Sponsored ADR (SLN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most pow…
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy. O…
Looking at Silence Therapeutics plc's (NASDAQ:SLN ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold. While we would nev…